Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsWPS Health Insurance drug Prior Auth Policy Update…
    Ask Trek AI about this page
    CurrentWPS Health InsurancePolicy N/A

    Drug prior authorization requirements

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Explains why certain drugs require prior authorization and describes who performs reviews, how drugs are listed, and where to obtain criteria. Applies to WPS Health Insurance members and providers using WPS-managed or partner pharmacy/medical benefit managers.

    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug prior authorization requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit prior authorization requests to the designated reviewer (ESI, CCUM, eviCore, or WPS) listed for each drug; if the external reviewer cannot complete the review, submit to WPS.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All drugsRequire prior authorization
    7/1/2026Policy effective
    1-800-475-1954Primary PA phone
    ESI/CCUM/eviCore/WPSReviewers

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Biosimilars & gene therapy
    Includes

    Coverage criteria and general policy stance

    General coverage stance

    Covered when meeting medical necessity and prior authorization requirements

    General PA requirement: All drugs on the published list require prior authorization before coverage will be approved.

    If third-party reviewers (ESI, CCUM, eviCore) cannot complete review, submit to WPS; if the group's PBM differs from ESI, submit to that PBM.

    Medical necessity: Coverage is subject to medical necessity; services deemed experimental, investigational, and/or unproven per clinical guidelines are not covered.

    General PA requirement

    Coverage stance for listed drugs

    PA requirement: Drug is covered only with prior authorization as indicated.

    Delegated reviewer or WPS routing required; follow per‑drug reviewer assignment.

    General PA coverage conditions

    Covered when routed through appropriate reviewer and PA is obtained

    PA requirement: Prior authorization is required for any drug listed in this document.

    Providers must submit to the reviewer noted for the drug (ESI, CCUM, eviCore) or to WPS if the external reviewer cannot complete the review.

    Reviewer routing: If an entry lists ESI, CCUM, or eviCore (with option numbers), submit PA requests to that reviewer; if the reviewer cannot complete the review or the PBM differs, submit to WPS or the alternate PBM as instructed.

    Reviewer contact numbers and submission instructions are provided in the document (Description, 4).

    General PA requirement

    Covered only with prior authorization

    PA requirement: All drugs listed require prior authorization; submissions must be routed to the reviewer indicated (ESI, CCUM, eviCore, or WPS) or to the PBM when applicable.

    See per‑drug entries for HCPCS/J‑codes, benefit type (P/M), and reviewer assignment.

    General coverage stance for listed drugs

    Covered only with prior authorization when submitted to the assigned reviewer or WPS

    PA required for listed drugs: All drugs on the list require prior authorization.

    Submit to the assigned reviewer (ESI, CCUM, eviCore) or to WPS if the reviewer cannot complete the review; if using a different PBM, submit to that PBM.

    Prior Authorization Requirement (general)

    Drugs on this list are subject to prior authorization review

    PA routing and reviewer: All listed drugs require prior authorization and must be submitted to the reviewer specified for each drug (ESI, CCUM, eviCore, or WPS).

    Reviewer contact numbers and per‑drug HCPCS/benefit type are provided in the document.

    General PA Requirement

    Covered when prior authorization is obtained

    PA requirement: All drugs listed in this document require prior authorization and must be submitted to the reviewer or PBM indicated for that drug (ESI, CCUM, eviCore, or WPS). If the assigned reviewer cannot complete the review, submit to WPS for evaluation. If using a PBM other than ESI through WPS, submit to that PBM.

    This section provides administrative routing and coding; clinical medical necessity criteria are handled by the assigned reviewer and are not detailed in these chunks.

    Prior authorization requirement (list-based)

    Covered when prior authorization is obtained for listed drugs

    PA required: All drugs on this list require prior authorization; submit to the designated reviewer (ESI, CCUM, eviCore) or to WPS if they cannot complete the review.

    Applies to every drug entry in this part of the list; follow per‑drug reviewer and code fields when submitting PA.

    Services that are considered experimental, investigational, or unproven under applicable clinical guidelines are not covered. Coverage for drugs and related services is subject to medical necessity review and will be denied when the requested use is judged to fall into these unproven categories.

    No specific exclusion conditions are identified in this section of the document. The listing is administrative and instructs that all drugs on the published list require prior authorization; routing and reviewer assignment are provided rather than discrete clinical exclusions.

    This excerpt does not present any explicit exclusions. Entries list products with benefit type, billing codes, reviewer assignment, and comments, and indicate that prior authorization is required for each listed drug.

    No drug-specific exclusions are provided in these chunks. The document emphasizes that every drug shown requires prior authorization, with per-drug reviewer routing and HCPCS/J-codes supplied for billing and submission.

    This portion of the material is administrative: it assigns the prior authorization requirement and the reviewer for each listed product. It does not contain clinical coverage criteria or explicit exclusions; providers should follow the PA routing and documentation fields included with each entry when submitting requests.

    No clinical coverage exclusions are specified in these chunks. The content is an administrative listing that indicates benefit type, HCPCS code, and the delegated reviewer; all listed drugs require prior authorization per the document instructions.

    There are no drugs identified as exempt in this excerpt. For listed products, the instruction is to submit prior authorization requests to the designated reviewer (ESI, CCUM, eviCore) or to WPS if the reviewer cannot complete the review.

    This section contains a list of products subject to prior authorization and routing instructions; it does not include explicit clinical exclusions. Providers must submit PA to the assigned reviewer (e.g., eviCore for oncology items) or to WPS for escalation.

    No explicit exclusions are provided in these chunks. The listing focuses on benefit type, HCPCS/administrative codes, reviewer assignment, and reviewer contact information for prior authorization submission.

    No exclusion conditions are specified here. The document reiterates that all drugs on the list require prior authorization and provides reviewer routing and HCPCS codes for each entry.

    This excerpt does not list exclusions. It shows biosimilar entries and confirms that each product on the PA list requires authorization and the reviewer assignment; follow the listed reviewer instructions when submitting requests.

    Requests for uses judged to be experimental, investigational, or unproven may be determined to be not medically necessary and therefore denied. Coverage determinations remain subject to the medical necessity standards of the member’s policy.

    These chunks do not specify particular conditions that would be labeled not medically necessary. The content is administrative and centers on assigning prior authorization and reviewer routing for listed drugs.

    No explicit not medically necessary criteria are provided in this portion of the document; the entries are administrative and indicate PA requirement and reviewer routing rather than clinical denial rules.

    Not applicable in this extract — these chunks do not present specific not medically necessary statements. The listing is focused on PA requirements and reviewer assignments.

    No explicit not medically necessary conditions are stated in this part of the document. Providers should follow the PA processes and reviewer routing shown for each drug to obtain a coverage determination.

    These chunks do not include discrete not medically necessary rules. The document reiterates administrative PA requirements and reviewer submission instructions for listed drugs.

    Billing codes and HCPCS/other code listings

    Sample listed HCPCS/Codes from drug listHCPCS
    J3490CMS miscellaneous drug code listed in the drug list entries (example: topical 5-fluorouracil, adapalene/benzoyl peroxide)
    J91905-fluorouracil injection (example from list)
    J0129Abatacept (example listed)
    J8999Unclassified antineoplastic drug (listed for multiple oral oncology agents)
    J9354Ado-trastuzumab emtansine (KADCYLA) (listed)
    J0172Aducanumab (ADUHELM) (listed)
    J7352Afamelanotide acetate (SCENESSE) (listed)
    Q2057HCPCS for afamitresgene autoleucel (TECELRA) (listed)
    Q5149Aflibercept-abzv biosimilar (ENZEEVU) (listed)
    J0180Agalsidase beta (FABRAZYME) (listed)
    Listed HCPCS/J-codes and related codesHCPCS
    Q5147HCPCS code for aflibercept-ayyh (biosimilar)
    Q5170HCPCS code for aflibercept-boav (biosimilar)
    Q5155HCPCS code for aflibercept-jbvf (biosimilar)
    Q5150HCPCS code for aflibercept-mrbb (biosimilar)
    Q5153HCPCS code for aflibercept-yszy (biosimilar)
    J0180HCPCS code for agalsidase beta
    J3490HCPCS code used for albiglutide, albuterol inhaler, many others
    J9015HCPCS code for aldesleukin
    J8999HCPCS code used for alectinib - oral and others
    J0202HCPCS code for alemtuzumab
    1–10 of 36
    1/4
    Sample HCPCS/J-codes from entriesHCPCS
    J7198listed with apalutamide
    J8999listed with apalutamide
    Additional HCPCS/J-codesHCPCS
    J9022atezolizumab
    J2782avacincaptad pegol
    Additional HCPCS/J-codesHCPCS
    J9053belantamab mafodotin-blmf
    J0485belatacept
    Q-codes for biosimilars/variantsHCPCS
    Q5129bevacizumab-adcd
    Q5107bevacizumab-awwb
    Sample HCPCS/J-codes in listHCPCS
    J0584burosumab-twza (example J-code listed)
    J0598c1 esterase inhibitor (example J-code listed)
    J0599HAEGARDA (example J-code listed)
    J0596RUCONEST (example J-code listed)
    J9043cabazitaxel (example J-code listed)
    J9064CABAZITAXEL (alternate J-code listed)
    J0739cabotegravir (example J-code listed)
    Additional HCPCS/J-codesHCPCS
    J9118asparlas / related oncology J-code
    J8499Miscellaneous drug J-code (appears repeatedly for pharmacy benefit items)
    J8522capecitabine - oral
    CAR-T and specialty codesHCPCS
    C9098CARVYKTI CAR-T therapy code
    Q2056CARVYKTI alternate code
    J0567cerliponase alfa
    Listed HCPCS/J/C/Q codes in this sectionmixed
    J0889daprodustat (example code listed)
    J9145daratumumab (example code listed)
    J0881darbepoetin alfa (example code listed)
    J0882darbepoetin alfa (alternate code listed)
    J9150daunorubicin (example code listed)
    J9153daunorubicin/cytarabine liposome (VYXEOS LIPOSOME)
    J0589daxibotulinumtoxinA-lanm (example code listed)
    J0894decitabine (example code listed)
    J0893decitabine (Sun Pharma) (example code listed)
    J8999multiple oral oncology or unspecified drug codes (used for several oral agents)
    1–10 of 35
    1/4
    HCPCS / placeholder codes shown in listHCPCS
    J8499Listed frequently as HCPCS placeholder code
    J8999Listed as HCPCS placeholder code
    J9177HCPCS code shown for enfortumab vedotin-ejfv
    J1325HCPCS code shown for epoprostenol sodium
    J0885HCPCS code shown for epoetin alfa
    Q5105HCPCS code shown for epoetin alfa-epbx
    J3032HCPCS code shown for eptinezumab-jjmr
    J9178HCPCS code shown for epirubicin
    J1305HCPCS code shown for evinacumab-dgnb
    J3590HCPCS code shown for several products (e.g., evolocumab)
    1–10 of 20
    1/2
    Sample HCPCS/J-codes present in listHCPCS
    J8499Listed as HCPCS code for multiple pharmacy benefit drugs (placeholder misc drug code)
    J3031HCPCS code listed for fremanezumab-vfrm
    J9395HCPCS code listed for fulvestrant
    J1595HCPCS code listed for glatiramer acetate (GLATOPA)
    J1628HCPCS code listed for guselkumab
    J1746HCPCS code listed for ibalizumab-uiy (TROGARZO)
    C9081HCPCS code listed for idecabtagene vicleucel
    Q2055HCPCS code listed for idecabtagene vicleucel
    S0132HCPCS code listed for ganirelix acetate
    J9201HCPCS code listed for gemcitabine
    1–10 of 12
    1/2
    Immune globulin HCPCS examplesHCPCS
    J1556HCPCS Code listed for BIVIGAM (immun glob g(igg)/gly/iga ov50)
    J1569HCPCS Code listed for GAMMAGARD LIQUID (immun glob g(igg)/gly/iga ov50)
    J1459HCPCS Code listed for PRIVIGEN (immun glob g(igg)/pro/iga 0-50)
    Additional immune globulin HCPCS examplesHCPCS
    J1559HCPCS Code listed for HIZENTRA (immun glob g(igg)/pro/iga 0-50)
    J1551HCPCS Code listed for CUTAQUIG (immun glob g(igg)-hipp/maltose)
    J1576HCPCS Code(s) listed for PANZYGA (immun glob g(igg)-ifas/glycine) - also J1599 referenced
    Immune globulin HCPCS continuedHCPCS
    J1566HCPCS Code listed for GAMMAGARD S-D
    J1561HCPCS Code listed for GAMUNEX-C / GAMMAKED
    J1568HCPCS Code listed for OCTAGAM
    Immune globulin HCPCS examplesHCPCS
    J1577HCPCS Code listed for QIVIGY XEMBIFY (immune globulin gamma(igg)klhw)
    J1558HCPCS Code listed for XEMBIFY (immune globulin gamma(igg)klhw)
    J1554HCPCS Code listed for ASCENIV (immune globulin gamma(igg)slra)
    Selected HCPCS codes (various drugs)HCPCS
    J0588HCPCS Code listed for incobotulinumtoxin A (XEOMIN)
    J1823HCPCS Code listed for inebilizumab-cdon (UPLIZNA)
    J1745HCPCS Code listed for infliximab (REMICADE)
    Infliximab biosimilars codingHCPCS
    Q5104HCPCS/secondary code listed for infliximab-abda (RENFLEXIS)
    Q5121HCPCS/secondary code listed for infliximab-axxq (AVSOLA)
    J1748HCPCS Code listed for infliximab-dyyb (INFLECTRA, ZYMFENTRA)
    Mixed HCPCS/Codes usedmixed
    C9399HCPCS code referenced for inotersen sodium (TEGSEDI)
    J9229HCPCS Code listed for inotuzumab ozogamicin (BESPONSA)
    J3490Generic HCPCS/unspecified drug code used for multiple pharmacy drugs (e.g., insulin entries, lifileucel, others)
    Unspecified/specialty HCPCS codesHCPCS
    J8499HCPCS/general oral/injectable unspecified code used for many oral specialty drugs
    J8999HCPCS unspecified code used for certain specialty or oral oncology agents
    J1961HCPCS Code listed for lenacapavir (SUNLENCA)
    HCPCS / J-codes referenced in listHCPCS
    J1954listed in table for leuprolide acetate/norethindrone (example)
    J1950listed in table for leuprolide-related entries (example)
    J9359loncastuximab tesirine-lpyl (ZYNLONTA) J-code
    J3490Miscellaneous drug code (used for multiple listed drugs)
    J8499Unclassified biologics/drugs (used for multiple listed drugs)
    J9223lurbinectedin (ZEPZELCA) J-code
    J9350mosunetuzumab-axgb (LUNSUMIO) J-code
    J9246melphalan flufenamide / melphalan related J-code
    J9248melphalan HCL inj J-code
    J0887methoxy peg-epoetin beta J-code
    1–10 of 12
    1/2
    Sample HCPCS/Codes from list (partial)HCPCS
    J9348naxitamab-gqgk
    J9295necitumumab
    J9261nelarabine
    Additional HCPCS/Codes (partial)HCPCS
    J2350ocrelizumab
    J2406oritavancin diphosphate
    J9263oxaliplatin
    NotesHCPCS
    J2507pegloticase
    J9226example not present (no inference)
    Sample HCPCS/J-codes (multiple entries across list)HCPCS
    J2508HCPCS/J-code listed for pegunigalsidase alfa / pegvaliase-pqpz
    J3490HCPCS/J-code listed for multiple drugs (pegunigalsidase alfa, pegvisomant, etc.)
    Additional HCPCS/Q-codesHCPCS
    J2778HCPCS/J-code listed for ranibizumab (LUCENTIS)
    Q5128HCPCS code listed for ranibizumab-eqrn (CIMERLI)
    Listed HCPCS/J-codesHCPCS
    J8499Miscellaneous HCPCS/J-code (as listed for many pharmacy products)
    J2820Sargramostim HCPCS (per document)
    J3590Sarilumab / similar J-code noted
    J2840Sebelipase alfa HCPCS
    C9166Secukinumab HCPCS
    J3247Secukinumab (IV) HCPCS
    J8999Oral oncology/other misc J-code used for many oral agents
    J9331Sirolimus protein-bound particles HCPCS
    J2941Somatropin HCPCS
    J1447tbo-filgrastim HCPCS
    1–10 of 28
    1/3
    Listed HCPCS/CodesHCPCS
    J8700temozolomide - oral
    J9328temozolomide - inj
    J9330temsirolimus
    J8499multiple drugs listed as J8499 (various pharmacy-coded drugs)
    J9381teplizumab-mzwv
    J8999multiple oral oncology/other agents
    J3241teprotumumab-trbw
    J3110teriparatide
    J3490various topical/ophthalmic/pharmacy items
    J3262tocilizumab
    1–10 of 37
    1/4
    HCPCS codes listed in excerptHCPCS
    J3380vedolizumab HCPCS code (as listed)
    J3385velaglucerase alfa HCPCS code (as listed)
    J0217velmanase alfa HCPCS code (as listed)
    J8499multiple oral/other drugs HCPCS code placeholder (as listed)
    J8999multiple oral oncology/other drugs HCPCS code placeholder (as listed)
    J3396verteporfin HCPCS code (as listed)
    J3397vestronidase alfa-vjbk HCPCS code (as listed)
    J1427viltolarsen HCPCS code (as listed)
    J0225vutrisiran HCPCS code (as listed)
    J7179von willebrand factor HCPCS code (as listed)
    1–10 of 24
    1/3
    inv-55: Effective date — 7/1/2026
    Effective dateEffective 7/1/2026
    Policy status

    What providers must do: submission, documentation, and denial risk

    Prior Authorization

    Prior authorization required for all listed drugs

    All drugs listed require prior authorization before coverage will be approved. If ESI, CCUM, or eviCore cannot complete the review, submit the request to WPS for evaluation; if the group's PBM differs from ESI, submit to that PBM as instructed.

    • PLEASE NOTE: All drugs on this list require a PA.
    • If ESI, CCUM, or eviCore cannot complete the review, submit to WPS for evaluation.
    • If using a PBM other than ESI through WPS, submit to the other PBM.
    Note

    Network-specific PA submission rules (AETNA/Auxiant groups)

    For WPS Powered by Auxiant groups using the AETNA Network, pharmacy benefit drugs require prior authorization through Express Scripts, eviCore, or WPS as indicated; medical benefit drugs do not require PA but a medical necessity review is recommended and notes should be faxed to American Health Holdings (AHH) as instructed.

    Initial therapy prior authorization requirements

    Initial therapy PA requirement

    General

    PA submission: Initial therapy with any drug on this list requires prior authorization routed to the designated reviewer listed for that drug.

    No additional clinical entry criteria are provided in these chunks; reviewers will apply clinical/medical necessity standards during the PA review.

    Step therapy and sequence information

    Note
    Step therapy and PA criteria are available from the designated reviewers: for Express Scripts or Care Continuum call 1-800-475-1954; for eviCore see https://www.evicore.com/provider/clinical-guidelines (search 'WPS Health Insurance').
    Observation
    No explicit step-therapy steps are listed in this section; entries provide benefit type and reviewer routing instead.
    Comment
    The document does not specify step therapy sequences; routing to ESI, CCUM, or eviCore for review may imply additional utilization management handled by those reviewers.
    Summary
    No required prior failures or explicit step sequencing are provided; the policy lists per-drug reviewer assignments (including 'see comments' where applicable) for clinical review.
    Interpretation
    Entries marked 'see comments' may indicate reviewer-specific or drug-specific utilization management steps are applied by the reviewer, but explicit step therapy algorithms are not present in the excerpt.
    Requirement
    Initial administrative requirement: submit prior authorization to the designated reviewer (ESI, CCUM, or eviCore) shown for each drug; if those reviewers cannot complete the review, submit to WPS for evaluation.
    Note
    No step therapy requirements are specified in these chunks; the list indicates PA is required and provides reviewer routing for each drug.
    Observation
    No explicit step therapy sequences are specified; reviewer assignment (ESI, CCUM, eviCore) and routing are the primary operational rules in these entries.
    Finding
    No explicit step therapy sequences or prior-failure requirements are listed; entries include reviewer routing and specialty flags (e.g., Oncology, MH/SUD) only.
    Routing Options
    Reviewer routing options are specified (ESI = option 1, CCUM = option 2, eviCore = option 3); the excerpt provides routing rather than explicit clinical step-therapy sequences.

    Site-of-care and benefit type guidance

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilar entries and special coding

    Note
    Note
    Note
    Note
    Note
    Note

    Field and term definitions

    inv-118: Prior authorization definition — utilization management tool to confirm appropriate use and medical necessity
    DefinitionA utilization management tool used to confirm appropriate use and medical necessity of certain drugs before coverage is approved.
    PurposeEnsures drugs meet medical necessity requirements and helps determine coverage; experimental/unproven services are not covered
    When to submitAll drugs on the published list require prior authorization and must be submitted to the assigned reviewer per the list
    inv-119: Benefit Type — P = Pharmacy, M = Medical
    PPharmacy benefit (P) — shown in Description, 2
    MMedical benefit (M) — shown in Description, 2

    Background and rationale

    Prior authorization is used to confirm the appropriate use of certain drugs and to determine whether a requested drug meets the medical necessity requirements of the member’s policy. It is an authorization step that must be completed before coverage will be approved for drugs on the list.

    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug prior authorization requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit prior authorization requests to the designated reviewer (ESI, CCUM, eviCore, or WPS) listed for each drug; if the external reviewer cannot complete the review, submit to WPS.
    SourceLink
    On This Page
    Coverage criteria and general policy stanceBilling codes and HCPCS/other code listingsWhat providers must do: submission, documentation, and denial riskInitial therapy prior authorization requirementsStep therapy and sequence informationSite-of-care and benefit type guidanceBiosimilar entries and special codingField and term definitionsBackground and rationale
    All drugs on this list require prior authorization; submit to designated reviewer (ESI, CCUM, eviCore) or to WPS if external reviewer cannot complete review
    Primary reviewer contactESI / eviCore / CCUM: 1-800-475-1954; WPS escalation: 1-800-333-5003
    Benefit type field meaningDescription field 2: P = Pharmacy; M = Medical
    inv-56: No numeric clinical thresholds in this extract
    Numeric clinical thresholdsNo numeric clinical thresholds in this extract
    ImplicationPolicy is an administrative PA-required drug list; clinical thresholds (dosage limits, lab values) are not provided in these chunks
    Where to find utilization criteriaObtain step therapy or clinical PA criteria from reviewers: Express Scripts / Care Continuum (call 1-800-475-1954) or eviCore (evicore.com)
    inv-57: (empty label) — fallback to source
    Fallback instructionIf per-drug reviewer cannot complete PA review, submit request to WPS for evaluation
    Coverage stanceCoverage is subject to medical necessity; services deemed experimental, investigational, or unproven will not be covered
    Definition - Prior authorizationA utilization management tool used to confirm appropriate use and medical necessity before coverage is approved
    inv-58: No numeric thresholds listed in this section
    Numeric thresholds in sectionNo numeric thresholds listed in this section
    Coding / billing guidancePer-drug entries include HCPCS/J-codes and benefit type (P = Pharmacy, M = Medical); use listed codes when submitting PA
    Reviewer routingSubmit PA to the reviewer listed for each drug (ESI, CCUM, eviCore) or to WPS if external reviewer cannot complete review
  1. Pharmacy Benefit (P): PA required via ESI, eviCore, or WPS as indicated.
  2. Medical Benefit (M): PA not required; perform medical necessity review and fax notes to AHH at 608-273-4554.
  3. Prior Authorization

    Submit PA to designated PBM/reviewer

    Submit prior authorization requests to the PBM or reviewer shown for each drug; if the PBM in use is not ESI, submit to that PBM per the listing.

    • Follow the reviewer assignment in the per‑drug entry (ESI, CCUM, eviCore, or WPS).
    • If the PBM differs from ESI, submit to the other PBM for pharmacy‑benefit drugs.
    Prior Authorization

    PA required; delegated reviewers perform reviews

    All drugs on the published list require prior authorization; reviews are performed by delegated reviewers (ESI, CCUM, eviCore) as indicated for each drug or submitted to WPS if those reviewers cannot complete the review.

    • Per‑drug entries list the designated reviewer; submit requests there first.
    • If external reviewer cannot complete the review, submit to WPS for evaluation.
    Prior Authorization

    Routing: use indicated PBM/reviewer or escalate to WPS

    If you use a PBM other than ESI, submit the PA to that PBM for drugs they review; if ESI, CCUM, or eviCore cannot complete the review, submit the request to WPS for evaluation.

    • Submit to the PBM/reviewer indicated in the per‑drug 'Reviewer' field.
    • Fallback: submit to WPS when the external reviewer cannot complete the review.
    Documentation Required

    PA required — include HCPCS/J‑codes and reviewer

    Prior authorization is required for the listed drugs; many entries include HCPCS/J‑codes and identify the reviewer organization that will process the PA request.

    • Include the HCPCS/J‑code shown in the per‑drug entry with your PA submission.
    • Use the reviewer assignment (ESI, CCUM, eviCore, or WPS) for routing.
    Prior Authorization

    Route PA to reviewer listed in column 4

    Submit prior authorization requests following the reviewer assignment shown in column 4 of each drug entry (ESI, CCUM, eviCore, or WPS); that reviewer will handle the PA processing.

    • Column 4 of each entry lists the designated reviewer and option number (e.g., ESI option 1, CCUM option 2, eviCore option 3).
    • If the designated external reviewer cannot complete the review, submit to WPS.
    Billing Rule

    PA required — include benefit type and HCPCS/admin codes

    Prior authorization is required for each listed drug; per‑drug entries include the benefit type (P = Pharmacy, M = Medical) and HCPCS/administration codes which should be used for billing and submission.

    • Reference the Benefit Type field (P or M) and HCPCS code in PA requests and claims.
    • Use the reviewer specified in the per‑drug record (ESI, CCUM, eviCore, or WPS).
    Documentation Required

    PA required — reviewer assigned with contact routing

    All drugs listed require prior authorization; the document identifies the responsible reviewer (ESI, CCUM, eviCore, or WPS) and provides contact/routing instructions.

    • Reviewer phone routing is provided in the Description, 4 field (ESI/CCUM/eviCore: 1‑800‑475‑1954; WPS: 1‑800‑333‑5003).
    • Follow the per‑drug reviewer assignment to determine where to submit the PA.
    Prior Authorization

    Submit to indicated PBM/reviewer or escalate to WPS

    Submit the PA to the PBM or reviewer indicated for the drug; if that reviewer cannot complete the review, submit to WPS for evaluation.

    • Designated reviewers include ESI, CCUM, eviCore (option numbers shown) or WPS.
    • Contact numbers are provided for vendor reviewers and WPS for escalation.
    Documentation Required

    Each drug mapped to benefit type, HCPCS/J‑codes, and reviewer

    Prior authorization is required for the listed drugs; the table associates each drug with benefit type, one or more HCPCS/J‑codes, and the designated reviewer responsible for the PA.

    • Per‑drug entries show Alt Descriptions, Benefit Type, HCPCS Code, Reviewer, and Drug Comments.
    • Providers should reference these fields when preparing PA submissions.
    Prior Authorization

    Submit PA to specified reviewer; fallback to WPS if needed

    Submit prior authorization requests to the specified reviewer shown for each drug; if that reviewer cannot complete the review, submit to WPS for evaluation.

    • If using a PBM other than ESI through WPS, submit to that PBM as instructed.
    • Fallback to WPS when delegated reviewers cannot complete the review.
    Prior Authorization

    Route PA to listed reviewer using provided contact avenues

    All drugs require prior authorization and submissions should be routed to the reviewer listed (ESI, CCUM, eviCore or WPS) based on the per‑drug 'Reviewer' field; use vendor contact avenues provided.

    • Reviewer assignments determine routing; eviCore commonly handles oncology agents.
    • Contact numbers and submission channels are provided in the per‑drug entries.
    Documentation Required

    PA required — HCPCS codes and reviewer assignment included

    Prior authorization is required for all drugs listed; each entry provides HCPCS/HCPCS‑like codes and assigns the reviewer (ESI, CCUM, eviCore, or WPS) to process the PA.

    • Include the HCPCS/HCPCS‑like code from the per‑drug entry in PA and billing documentation.
    • Submit to the reviewer assigned in the drug entry.
    Prior Authorization

    Submit PA to designated reviewer or PBM; escalate to WPS if needed

    Submit the PA to the reviewer/PBM indicated for the drug (ESI, CCUM, eviCore); if they cannot complete the review, submit to WPS. If your group uses a PBM other than ESI through WPS, submit to that PBM.

    • Designated reviewers and PBM routing are shown for each drug entry.
    • WPS serves as the escalation path when delegated reviewers cannot complete review.
    Prior Authorization

    Escalate PA to WPS when external reviewer cannot complete review

    If an external reviewer (ESI, CCUM, eviCore) cannot complete the review, submit the prior authorization request to WPS for evaluation; providers should follow the submission instructions for the designated reviewer first.

    • Submit to the per‑drug reviewer initially; escalate to WPS when review cannot be completed externally.
    • WPS contact number is provided for escalation.
    Note

    Where to obtain PA and step‑therapy criteria

    Step therapy and prior authorization criteria for drugs reviewed by Express Scripts or Care Continuum are available by calling 1-800-475-1954; eviCore criteria are available at evicore.com and gene therapy coverage should be confirmed with WPS Customer Service.

    • Express Scripts / Care Continuum PA/step therapy: call 1-800-475-1954.
    • eviCore clinical guidelines: https://www.evicore.com/provider/clinical-guidelines (search for 'WPS Health Insurance').
    • Confirm Gene Therapy coverage with WPS Customer Service (member card number).
    Step Therapy

    Step therapy not specified in this section

    Per‑drug entries generally do not specify step therapy algorithms in this section; many entries include reviewer routing or 'see comments' rather than explicit step therapy steps.

    • Some entries show 'see comments' or reviewer‑specific notes that may indicate additional utilization management handled by the reviewer.
    • No explicit step therapy sequences or required prior failures are provided in these chunks.
    Step Therapy

    No explicit step therapy rules in per‑drug listings

    This section does not include explicit step therapy rules; per‑drug reviewer routing and comments are provided instead and may indicate reviewer‑specific requirements.

    • Entries with 'see comments' may reflect additional utilization management by the assigned reviewer.
    • Providers should consult the reviewer or the contact listed for specific PA/step therapy criteria.
    Note
    Note
    Note
    Documentation Required

    Follow reviewer comments for additional requirements

    Some per‑drug entries include 'see comments' which indicates that additional reviewer‑specific or drug‑specific requirements may apply; providers should follow reviewer guidance for those items.

    • When 'see comments' appears, consult the designated reviewer (ESI/CCUM/eviCore) for any additional submission requirements.
    • Reviewer may require supporting documentation or different routing depending on drug specialty.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Documentation used in PA reviews — supply medical records and references

    Medical records describing the patient's condition and prior treatments, FDA labeling, peer‑reviewed literature, and evidence‑based guidelines are used during PA review and should be made available to reviewers.

    • Provide medical records and prior treatment history with PA requests when relevant.
    • Reviewers will reference FDA labeling and clinical literature in coverage determinations.
    Documentation Required

    Where to submit prior authorization requests

    Submit PA requests to the listed reviewer (ESI, CCUM, eviCore) shown for each drug; if the third‑party reviewer cannot complete the review, submit to WPS using the contact information provided.

    • Reviewer contact avenues and option numbers are provided in Description, 4 of each entry.
    • WPS contact provided for escalation when vendor reviewers cannot complete review.
    Documentation Required

    Include HCPCS/billing code and benefit type on PA submissions

    Include the per‑drug HCPCS/ billing code and benefit type (P = Pharmacy, M = Medical) when submitting PA requests so the reviewer can correctly route and process the request.

    • Description fields: 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments.
    • Providers should supply the HCPCS/J‑code and benefit type from the per‑drug entry on the PA request.
    Billing Rule

    Use listed HCPCS/J‑codes and reviewer contacts for submissions

    Reference the HCPCS/J‑codes and benefit type listed for each drug when preparing claims or PA submissions and use the reviewer contact numbers if clarification or additional information is needed.

    • Per‑drug entries include HCPCS/HCPCS‑like codes to be used for billing and routing.
    • Use the reviewer phone numbers shown in the document for submission or questions.
    Documentation Required

    Provide per‑drug description fields with PA requests

    Each drug entry contains fields (alternate description, benefit type, HCPCS code, reviewer, drug comments); providers should supply this information with PA requests to ensure accurate routing and review.

    • Description, 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments.
    • Providing all fields reduces delays and supports reviewer evaluation.
    Documentation Required

    Submit PA to the designated reviewer using provided contacts

    The table provides HCPCS/administrative codes and the designated reviewer to contact (ESI, CCUM, eviCore, or WPS) for PA processing; contact numbers are listed for reviewers and WPS for escalation.

    • Submit to the designated reviewer indicated in the per‑drug entry.
    • If the designated reviewer cannot complete review, use WPS contact for escalation.
    Billing Rule

    Use benefit type and HCPCS codes for billing and routing

    Per‑drug entries include benefit type and HCPCS codes that should be used for billing and reviewer routing; include the appropriate HCPCS/J‑code and benefit type when submitting the PA.

    • Benefit Type: P = Pharmacy, M = Medical.
    • Include the HCPCS/J‑code listed in Description, 3 on PA forms and claims.
    Documentation Required

    Designated reviewer submission and escalation contacts

    Submit PA requests to the designated reviewer (ESI, CCUM, or eviCore) shown for each drug; if those reviewers cannot complete the review, submit to WPS for evaluation. Contact numbers for ESI/eviCore (1‑800‑475‑1954) and WPS (1‑800‑333‑5003) are provided.

    • ESI/eviCore phone: 1‑800‑475‑1954.
    • WPS phone for escalation: 1‑800‑333‑5003.
    Documentation Required

    Use reviewer routing and contact info from the table

    Reviewer contact information and reviewer assignment are provided in the per‑drug entries; submit PA to the listed reviewer (ESI, CCUM, eviCore) or to WPS if external reviewers cannot complete the review.

    • Reviewer assignments appear in Description, 4 for each drug entry.
    • Use the provided phone numbers for submission or questions.
    Documentation Required

    Required documentation elements for PA submission

    Each drug entry includes alternate descriptions, benefit type (P = Pharmacy), HCPCS/billing code, reviewer assignment (ESI, CCUM, eviCore, or WPS) and drug comments; providers should submit PA requests to the assigned reviewer or to WPS if the reviewer cannot complete the review.

    • Include alternate description and HCPCS code to ensure correct review routing.
    • Follow reviewer assignment; escalate to WPS when necessary.
    Documentation Required

    Reviewer routing and escalation contact information

    Reviewer contact routing is provided: ESI, CCUM, and eviCore have phone numbers for submission and WPS is the escalation contact when external reviewers cannot complete review.

    • Use vendor reviewer contact for initial submission; escalate to WPS if vendor cannot complete review.
    • Reviewer contact numbers are included in the per‑drug entries.
    Prior Authorization

    Route PA to listed reviewer; use WPS if vendor cannot complete review

    PA submissions should be routed to the listed reviewer per drug (ESI, CCUM, eviCore or WPS) using the provided contact numbers when a vendor cannot complete the review.

    • Submit to the reviewer indicated in the per‑drug 'Reviewer' field.
    • When the reviewer cannot complete the review, submit to WPS using the escalation contact.
    Documentation Required

    Submit PA to designated reviewer/PBM with required codes

    Providers must submit PA requests to the designated reviewer/PBM listed for each drug (ESI, CCUM, eviCore, or WPS) using the contact avenues noted; include the HCPCS/billing code and benefit type from the per‑drug entry.

    • Designated reviewer is shown in each entry; use their contact channel for PA submission.
    • Include HCPCS code and benefit type to avoid processing delays.
    Documentation Required

    Reviewer contact numbers and submission routing for escalation

    Reviewer contact numbers and reviewer assignment (ESI, CCUM, eviCore, or WPS) are provided for submission if external reviewers cannot complete the review; use these contacts for escalation.

    • Contact numbers for reviewers and WPS are provided in the document.
    • Escalate to WPS when delegated reviewers cannot complete review.
    Denial Risk

    Denial risk for experimental/investigational services

    Services deemed experimental, investigational, and/or unproven under clinical guidelines will not be covered and may be denied; ensure requested use aligns with accepted clinical guidance.

    • Requests for indications considered experimental, investigational, or unproven may be determined not medically necessary and denied.
    • Provide supporting clinical evidence when requesting coverage for non‑standard uses.
    Denial Risk

    Denial risk if PA not obtained for listed drugs

    Failure to submit a prior authorization for any drug on this list may result in denial or deferral of coverage because the policy states that all drugs on the list require a PA.

    • PLEASE NOTE: All drugs on this list require a PA.
    • Claims for listed drugs may be denied if PA is not obtained and submitted to the listed reviewer.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    UsageBenefit Type field is provided per-drug to indicate billing and reviewer routing
    inv-120: Reviewer — Delegated reviewers: ESI, CCUM, eviCore, or submit to WPS when reviewers cannot complete review
    Delegated reviewersESI, CCUM, eviCore—submit to WPS if they cannot complete the review
    EscalationIf PBM other than ESI is used, submit to that PBM per instructions
    Contact infoReviewer phone numbers provided in Description, 4 (e.g., ESI/eviCore: 1-800-475-1954; WPS: 1-800-333-5003)
    inv-121: Benefit Type field mapping — P = Pharmacy and M = Medical as indicated in the list
    Field mappingDescription, 2 = Benefit Type (P = Pharmacy; M = Medical)
    Per-drug useInclude Benefit Type when submitting PA to ensure proper routing and billing
    Document referenceBenefit Type mapping appears in multiple per-drug Description fields across the list
    inv-122: Reviewer field mapping — Field 'Description, 4' identifies PA reviewer with contact numbers
    Field identificationDescription, 4 identifies the PA reviewer (ESI, CCUM, eviCore) and includes contact numbers; submit to WPS if reviewers cannot complete review.
    Routing optionsSome entries note options (e.g., ESI option 1, CCUM option 2, eviCore option 3) to indicate reviewer routing
    Escalation contactWPS contact provided for escalation: 1-800-333-5003
    inv-123: Drug Comments — Field 'Description, 5' contains shorthand such as MH/SUD or Oncology
    Drug comments fieldDescription, 5 contains shorthand such as MH/SUD (mental health/substance use disorder) or Oncology to indicate specialty routing or program
    Reviewer-specific notes'See comments' may indicate additional reviewer-specific requirements handled by the assigned reviewer
    Use in submissionInclude Description, 5 information when relevant to help reviewer assignment and processing
    inv-124: Benefit type / reviewer codes — P = Pharmacy; M = Medical; HCPCS Code = reported code; Reviewer = designated PA reviewer
    Code and reviewer mappingPer-drug entries include: Benefit Type (P/M), HCPCS code, and designated Reviewer (ESI, CCUM, eviCore, or WPS)
    HCPCS reportingHCPCS code field reports the code to use for medical-billed drugs and claim submission
    Reviewer roleReviewer listed is responsible for PA processing; submit to WPS if external reviewer cannot complete review
    inv-125: Benefit Type — P = Pharmacy, M = Medical
    Benefit Type codesP = Pharmacy; M = Medical
    Location implicationM designation often indicates medical/infusion billing and different reviewer routing
    Per-drug inclusionBenefit Type must be included on PA submissions to ensure correct processing
    inv-126: Per-drug Description fields — 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments
    Description field orderPer-drug Description fields: 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments
    Submission guidanceProviders should reference these fields when completing PA requests to supply required billing and routing information
    ConsistencyThis format is repeated across per-drug entries in the list
    inv-127: P — Benefit Type: Pharmacy
    PBenefit Type: Pharmacy
    ImplicationIndicates pharmacy benefit billing and reviewer routing for PA
    Example useShown in Description, 2 for many drugs (e.g., filgrastim as P)
    inv-128: M — Benefit Type: Medical or Mixed
    MBenefit Type: Medical (administration/infusion) or Mixed
    ImplicationIndicates medical benefit billing (facility/infusion) and may route to medical reviewers like CCUM or eviCore
    Example useShown in Description, 2 for many infusion/IV agents (e.g., ciltacabtagene autoleucel)
    inv-129: Description fields — Format mapping for per-drug fields
    Field formatDescription fields format — 1: Alt Descriptions; 2: Benefit Type; 3: HCPCS Code; 4: Reviewer; 5: Drug Comments
    Provider actionInclude the appropriate Description field values when submitting PA to facilitate routing
    DocumentationThis mapping appears in the header and per-drug entries throughout the list
    inv-130: Benefit Type — Indicates Pharmacy (P) or Medical (M) benefit for the listed drug
    Benefit Type indicatorIndicates Pharmacy (P) or Medical (M) benefit for the listed drug
    PurposeUsed to determine billing route and appropriate reviewer assignment
    Location in docPresented in Description, 2 for each drug entry
    inv-131: Reviewer options — Specifies entity responsible for PA review: ESI, CCUM, eviCore, or WPS
    Reviewer optionsESI, CCUM, eviCore, or WPS are specified as the entity responsible for PA review
    Routing notesSome entries include option numbers (e.g., ESI option 1, CCUM option 2, eviCore option 3) to indicate routing pathways
    Escalation pathIf external reviewers cannot complete review, submit to WPS for evaluation